Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Mod Rheumatol ; 32(2): 380-386, 2022 Feb 28.
Article in English | MEDLINE | ID: mdl-34894250

ABSTRACT

OBJECTIVES: To estimate eosinophilic granulomatosis with polyangiitis (EGPA) prevalence and disease burden in patients with newly diagnosed EGPA in Japan. METHODS: This retrospective descriptive cohort study (GSK ID: 209751, HO-18-19652) used administrative claim data from patients (aged ≤74 years) with EGPA (study period: January 1, 2005-December 31, 2017), identified from their first ICD-10 code for EGPA (index). Data were examined during the 12 months before (baseline) and 12 months following the index date (follow-up). EGPA prevalence, respiratory comorbidities, all-cause healthcare utilization, and oral corticosteroid (OCS) use were assessed. RESULTS: EGPA prevalence (95%CI) increased from 4.2 (0,23.7)/million people (2005) to 38.0 (31.8,45.1)/million people (2017), was generally more common in females versus males, and increased with age. Of the 45 patients with newly diagnosed EGPA, 57.8% had acute bronchitis and 42.2% had upper respiratory tract infections during baseline. During follow-up, 60.0% of patients were hospitalized at least once and 77.8% used OCS (OCS dependent [≥80% of days]: 73.1%). CONCLUSIONS: In Japan, EGPA prevalence increased over time, was generally more common in females, and increased with patient age. EGPA burden was high; respiratory comorbidities were common, and most patients required hospitalization and OCS use. Our data suggest additional EGPA treatment options are needed.


Subject(s)
Churg-Strauss Syndrome , Granulomatosis with Polyangiitis , Aged , Churg-Strauss Syndrome/diagnosis , Churg-Strauss Syndrome/epidemiology , Cohort Studies , Cost of Illness , Female , Granulomatosis with Polyangiitis/diagnosis , Granulomatosis with Polyangiitis/drug therapy , Granulomatosis with Polyangiitis/epidemiology , Humans , Japan/epidemiology , Male , Patient Acceptance of Health Care , Prevalence , Retrospective Studies
2.
Int J Pharm ; 545(1-2): 19-26, 2018 Jul 10.
Article in English | MEDLINE | ID: mdl-29702241

ABSTRACT

The present study aimed to clarify the applicability of a self-micellizing solid dispersion of tranilast (SMSD/TL) to the treatment of inflammatory bowel diseases (IBD) using an experimental colitis model. SMSD/TL with several loading amounts ranging from 10 to 50% was prepared using a wet-milling system. The physicochemical properties of SMSD/TL were evaluated in terms of the dissolution behavior, morphology, and particle size distribution. Animal studies were conducted to evaluate oral bioavailability in rats and anti-inflammatory effects in a rat model of chemically induced colitis. SMSD/TL with drug loading of 15% (SMSD/TL15) showed enhanced dissolution behavior at pH 1.2, compared with other tested other formulations. After the dispersion of SMSD/TL15 in deionized water, fine micelles formed with an average diameter of 137 nm. SMSD/TL15 (10 mg-TL/kg) exhibited about 147- and 34-fold greater value for Cmax and the area under the curve of plasma concentration vs. time than crystalline TL, respectively. Although the anti-inflammatory effect on the colitis model was very limited in the crystalline TL (2 mg/kg) group, inflammatory events, such as myeloperoxidase activity and thickening of the submucosa in colon tissues, were significantly suppressed in the SMSD/TL15 (2 mg-TL/kg) group. Based on these findings, SMSD/TL might be a more efficacious dosage option for improved IBD treatment.


Subject(s)
Anti-Infective Agents/administration & dosage , Colitis/drug therapy , Colon/drug effects , Drug Carriers , Gastrointestinal Agents/administration & dosage , Intestinal Mucosa/drug effects , ortho-Aminobenzoates/administration & dosage , Administration, Oral , Animals , Anti-Infective Agents/chemistry , Anti-Infective Agents/pharmacokinetics , Biological Availability , Colitis/chemically induced , Colitis/metabolism , Colitis/pathology , Colon/metabolism , Colon/pathology , Disease Models, Animal , Drug Compounding , Gastrointestinal Agents/chemistry , Gastrointestinal Agents/pharmacokinetics , Hydrogen-Ion Concentration , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Male , Micelles , Neutrophil Infiltration/drug effects , Particle Size , Peroxidase/metabolism , Rats, Sprague-Dawley , Solubility , Technology, Pharmaceutical/methods , Trinitrobenzenesulfonic Acid , ortho-Aminobenzoates/chemistry , ortho-Aminobenzoates/pharmacokinetics
3.
Drug Metab Pharmacokinet ; 32(5): 273-276, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28923421

ABSTRACT

The present study was aimed to avoid pharmacokinetic transitions of itraconazole (ITZ) evoked by high-fat meal intake by employing a self-micellizing solid dispersion (SMSD) approach. The dissolution behavior of SMSD/ITZ was assessed in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). To evaluate the food effect on the oral absorption profile of ITZ, a pharmacokinetic study was conducted on orally-dosed ITZ samples in fasted and high-fat meal-fed rats. Crystalline ITZ showed a 9.0-fold higher dissolution amount of ITZ in fed-state SGF (FeSSGF) than in fasted-state SGF (FaSSGF), whereas there was no significant difference in the dissolution amount of ITZ in SMSD/ITZ between FeSSGF and FaSSGF. In fed- and fasted-state SIF, SMSD/ITZ exhibited reduced variation of ITZ dissolution, possibly leading to suppression of the food effect on the dissolution behavior of ITZ. After the oral administration of crystalline ITZ to high-fat meal-fed rats, the oral bioavailability of ITZ was 14-fold higher than that in fasted rats. In contrast, orally-dosed SMSD/ITZ in fed rats exhibited limited transition of pharmacokinetic behavior regardless of food intake due to the improvement in the dissolution behavior of ITZ even under fasted conditions. SMSD technology could be an efficacious dosage option for the consistent oral absorption and clinical outcomes of ITZ.


Subject(s)
Diet, High-Fat/adverse effects , Itraconazole/administration & dosage , Itraconazole/pharmacokinetics , Micelles , Absorption, Physiological , Administration, Oral , Animals , Body Fluids/drug effects , Dose-Response Relationship, Drug , Male , Rats , Rats, Sprague-Dawley
4.
Chem Pharm Bull (Tokyo) ; 65(5): 426-431, 2017.
Article in English | MEDLINE | ID: mdl-28458364

ABSTRACT

The aim of this study was to develop a pH-independent release formulation of dipyridamole (DP) by the combined use of pH-modifier technology and solid dispersion (SD) technology employing enteric polymer, Eudragit® S100 (Eud). Tartaric acid (TA) was selected as an appropriate pH-modifier in terms of improving the dissolution behavior of DP under neutral conditions. Upon optimization of the ratio of TA to DP, SD of DP with Eud and TA (SD-Eud/DP/TA) was prepared by a freeze-drying method. Scanning electron microscopic images revealed that DP was dispersed in the polymer in SD-Eud/DP/TA, and DP in SD-Eud/DP/TA was in an amorphous state, supported by powder X-ray diffraction and differential scanning calorimetry analyses. The dissolution behavior of SD-Eud/DP/TA was not dependent on the pH of the medium, although SD-Eud/DP exhibited very limited dissolution behavior under neutral conditions. Spectroscopic analysis suggested that there might be inter-molecular interaction among DP, TA and enteric polymer in SD-Eud/DP/TA, possibly leading to the stable pH-independent dissolution behavior of SD-Eud/DP/TA. TA in SD-Eud/DP/TA promoted the degradation of DP, suggesting that improving the stability of DP in SD-Eud/DP/TA might be key for its practical use. From these results, pH-independent dissolution behavior of SD-Eud/DP/TA could be achieved by an enteric polymer-based solid dispersion with a pH-modifier.


Subject(s)
Dipyridamole/chemistry , Technology, Pharmaceutical , Calorimetry, Differential Scanning , Hydrogen-Ion Concentration , Powder Diffraction , Solubility
5.
Biomed Pharmacother ; 90: 842-849, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28437888

ABSTRACT

The present study aimed to verify the efficacy of tranilast (TL) for treating inflammatory bowel disease (IBD) with the use of an experimental colitis model. The experimental colitis model was prepared by intrarectal instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS; 40mg/kg) dissolved in water containing 25% ethanol. The pharmacological effects of TL after repeated oral administration were evaluated by biomarker and histological analyses, and the pharmacokinetic behavior of TL was also examined after single oral administration. The intrarectal instillation of TNBS solution caused colitis, as evidenced by ca. 2.2-, 5-, and 3-fold increases in myeloperoxidase (MPO) activity, infiltrated cell numbers, and the thickness of the submucosa in the colon, respectively. However, orally-taken TL (10mg/kg, twice a day for 9days) led to a 92% reduction in the increase of the MPO level by TNBS enema, and cellular infiltration and thickened submucosa in the experimental colitis model tended to also be suppressed by repeated oral administration of TL. The oral bioavailability of TL in TNBS-treated rats was calculated to be as low as ca. 6.5%, and the poor oral absorption of TL may be a limitation of the treatment for IBD. TL could attenuate TNBS-induced colitis on the basis of the obtained results, and the anti-inflammatory effects would have clinical relevance to the therapeutic outcomes of TL in IBD patients. Although further improvement in the oral bioavailability of TL might be required for better pharmacological outcomes, TL would be an efficacious agent for treating IBD.


Subject(s)
Colitis/drug therapy , Protective Agents/pharmacology , ortho-Aminobenzoates/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Colitis/metabolism , Colon/drug effects , Colon/metabolism , Disease Models, Animal , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/metabolism , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Male , Peroxidase/metabolism , Rats , Rats, Wistar , Trinitrobenzenesulfonic Acid/pharmacology
6.
Eur J Pharm Sci ; 97: 55-61, 2017 Jan 15.
Article in English | MEDLINE | ID: mdl-27810562

ABSTRACT

The present study was aimed to evaluate the applicability of a self-micellizing solid dispersion (SMSD) system of itraconazole (ITZ) with the use of Soluplus® to achieve improved dissolution and stable oral absorption of ITZ under hypochlorhydric conditions. The SMSD of ITZ (SMSD/ITZ) was prepared by the freeze-drying method. Physicochemical properties of SMSD/ITZ were assessed in terms of morphology, crystallinity, particle size, thermal behavior, dissolution profile, and stability. The pharmacokinetic profile of SMSD/ITZ was evaluated in both normal rats and omeprazole-treated rats as a hypochlorhydric model. From the crystallinity assessment, ITZ in SMSD/ITZ might exist in an amorphous state. The dissolution behavior of SMSD/ITZ was markedly improved under both acidic and neutral conditions through the formation of nano-micelles with a diameter of 127nm. The degradation of ITZ in SMSD/ITZ was negligible after storage under accelerated conditions at 40°C or 40°C/75%RH for 4weeks. Under light exposure, ca. 33% of ITZ in SMSD/ITZ was degraded, suggesting the need for protection from light. Although the oral absorption of crystalline ITZ was negligible, SMSD/ITZ showed an improved pharmacokinetic profile in normal rats, with an absolute bioavailability (BA) of 2.9%, and even 6.3% in the hypochlorhydric model. From these findings, SMSD technology could be beneficial for improving the absorption profiles of weak basic drugs, even in hypochlorhydric patients.


Subject(s)
Achlorhydria/metabolism , Antifungal Agents/metabolism , Intestinal Absorption/physiology , Itraconazole/metabolism , Micelles , Polyethylene Glycols/metabolism , Polyvinyls/metabolism , Achlorhydria/drug therapy , Administration, Oral , Animals , Antifungal Agents/administration & dosage , Antifungal Agents/chemistry , Cell Line , Drug Liberation/drug effects , Drug Liberation/physiology , Intestinal Absorption/drug effects , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Itraconazole/administration & dosage , Itraconazole/chemistry , Male , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/chemistry , Polyvinyls/administration & dosage , Polyvinyls/chemistry , Rats , Rats, Sprague-Dawley , X-Ray Diffraction
7.
Int J Pharm ; 499(1-2): 255-262, 2016 Feb 29.
Article in English | MEDLINE | ID: mdl-26748364

ABSTRACT

PURPOSE: The present study aimed to develop an inhalable self-micellizing solid dispersion of tranilast (SMSD/TL) using poly[MPC-co-BMA] to improve the therapeutic potential and safety. METHODS: The safety of poly[MPC-co-BMA] in lungs was assessed using rat lung epithelium-derived L2 cells. SMSD/TL and respirable powder of SMSD/TL (SMSD/TL-RP) were prepared using a wet milling system and jet mill, respectively. The physicochemical properties of TL formulations were characterized in terms of dissolution, morphology, and particle size. Pharmacological and pharmacokinetic studies were also conducted on inhaled SMSD/TL-RP. RESULTS: The lactate dehydrogenase level from L2 cells treated with poly[MPC-co-BMA] was lower than that with polysorbate 80, a positive control. SMSD/TL showed enhanced dissolution behavior of TL. The jet milled SMSD/TL particles easily separated from the lactose carrier, and the particle size was suitable for inhalation. Compared with RP of TL, inhaled SMSD/TL-RP (100 µg-TL/rat) could more strongly suppress the inflammatory responses in antigen-sensitized rats. The TL level in plasma after intratracheal administration of SMSD/TL-RP at a pharmacological effective dose (100 µg-TL/rat) was ca. 4.2-fold lower than that after oral administration of TL solution at a clinical dose (1.67 mg/kg). CONCLUSION: SMSD/TL-RP might be an attractive dosage form to improve the anti-inflammatory effects and safety of TL.


Subject(s)
Anti-Allergic Agents/administration & dosage , Methacrylates/chemistry , Phosphorylcholine/analogs & derivatives , Technology, Pharmaceutical/methods , ortho-Aminobenzoates/administration & dosage , Administration, Inhalation , Animals , Anti-Allergic Agents/pharmacology , Anti-Allergic Agents/toxicity , Chemistry, Pharmaceutical/methods , Lactose/chemistry , Lung/drug effects , Lung/metabolism , Male , Micelles , Particle Size , Phosphorylcholine/chemistry , Powders , Rats , Rats, Sprague-Dawley , Respiratory Mucosa/metabolism , Solubility , ortho-Aminobenzoates/pharmacology , ortho-Aminobenzoates/toxicity
8.
Chem Pharm Bull (Tokyo) ; 63(1): 54-8, 2015.
Article in English | MEDLINE | ID: mdl-25743195

ABSTRACT

The main purpose of the present study was to evaluate the physicochemical stability of cyclosporine A (CsA)-loaded glycerol monooleate-based dry emulsion (DE). DE formulations containing 5-25% CsA (DE5-25) were stored at 25°C/60% relative humidity for 4 weeks, and freeze-dried solid dispersion formulations containing 5-30% CsA (FD5-30) were also prepared as reference formulations. Even after the storage, no significant changes were observed in the appearance of any formulations. In the dissolution study, both DE and FD exhibited marked enhancement of solubility and there was at least 2.0-fold improvement in the initial dissolution rate of DE formulations compared with that of FD formulations. After storage, DE5, DE15 and FD5 maintained relatively high solubility, with 10% reduction compared with the initial state. However, the solubility of DE25 gradually decreased during storage, as evidenced by 76% reduction of the dissolution amount. No significant changes were seen in DE5-25 using powder X-ray diffraction, although thermal analysis revealed moderate changes in crystallinity in DE25 after storage, possibly leading to the decreased dissolution. Furthermore, particle size distributions of micelles in DE5 and DE15 were almost unchanged after storage for 4 weeks. From these findings, it appears that the physicochemical stability of CsA-loaded DE might vary depending on the manufacturing method and that further optimization could improve physical properties and stability.


Subject(s)
Cyclosporine/chemistry , Emulsions/chemistry , Chemistry, Pharmaceutical , Drug Stability , Freeze Drying , Glycerides/chemistry , Light , Particle Size , Scattering, Radiation , Solubility
9.
Eur J Pharm Sci ; 62: 16-22, 2014 Oct 01.
Article in English | MEDLINE | ID: mdl-24836392

ABSTRACT

The present study aimed to develop a self-micellizing solid dispersion (SMSD) of cyclosporine A (CsA) using an amphiphilic block copolymer, poly[MPC-co-BMA], to improve the biopharmaceutical properties of CsA. The cytotoxicity of poly[MPC-co-BMA] was assessed in rat intestinal IEC-6 cells, and the pMB was less cytotoxic than polysorbate 80, a non-ionic surfactant with a wide safety margin. SMSD/CsA was prepared using a wet-milling system, and its physicochemical properties were characterized in terms of morphology, crystallinity, dissolution, particle size distribution, and stability. The SMSD/CsA exhibited immediate formation of fine micelles with a mean diameter of ca. 180 nm when introduced into aqueous media. There was marked improvement in the dissolution behavior of the SMSD/CsA compared with amorphous CsA. Even after storage at 40°C/75% relative humidity, the dissolution behavior of aged SMSD/CsA seemed to be almost identical to that of its freshly prepared equivalent, and CsA in aged SMSD/CsA was still in amorphous form. After oral administration of SMSD/CsA (10 mg CsA/kg) in rats, enhanced CsA exposure was observed with increases of Cmax and BA by ca. 11- and 42-fold, respectively, compared with those of amorphous CsA. The poly[MPC-co-BMA]-based SMSD formulation system might be an efficacious dosage option for CsA to achieve improvements in oral bioavailability.


Subject(s)
Cyclosporine , Immunosuppressive Agents , Methacrylates/chemistry , Micelles , Phosphorylcholine/analogs & derivatives , Animals , Biological Availability , Cell Line , Cell Survival/drug effects , Chemistry, Pharmaceutical , Cyclosporine/administration & dosage , Cyclosporine/blood , Cyclosporine/chemistry , Cyclosporine/pharmacokinetics , Drug Stability , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/blood , Immunosuppressive Agents/chemistry , Immunosuppressive Agents/pharmacokinetics , Male , Phosphorylcholine/chemistry , Rats, Sprague-Dawley , Solubility
10.
Int J Pharm ; 452(1-2): 220-6, 2013 Aug 16.
Article in English | MEDLINE | ID: mdl-23694807

ABSTRACT

The present study aimed to develop novel solid dispersion (SD) of tranilast (TL) using amphiphilic block copolymer, poly[MPC-co-BMA] (pMB), to improve the dissolution and pharmacokinetic behavior of TL. pMB-based SD of TL (pMB-SD/TL) with drug loading of 50% (w/w) was prepared by wet-mill technology, and the physicochemical properties were characterized in terms of morphology, crystallinity, dissolution, and hygroscopicity. Powder X-ray diffraction and polarized light microscopic experiments demonstrated high crystallinity of TL in pMB-SD/TL. The pMB-SD/TL exhibited immediate micellization when introduced to aqueous media, forming fine droplets with a mean diameter of ca. 122 nm. There was marked improvement in the dissolution behavior for the pMB-SD/TL even under acidic conditions, although the supersaturated TL concentration gradually decreased. NMR analyses demonstrated interaction between TL and pMB, as evidenced by the chemical shift drifting and line broadening. Pharmacokinetic behaviors of orally dosed TL formulations were evaluated in rats using UPLC/ESI-MS. After oral administration of pMB-SD/TL (10mg TL/kg) in rats, enhanced TL exposure was observed with increases of Cmax and AUC by 125- and 52-fold, respectively, compared with those of crystalline TL. From these findings, pMB-based SD formulation approach might be an efficacious approach for enhancing the therapeutic potential of TL.


Subject(s)
Anti-Allergic Agents/administration & dosage , Drug Delivery Systems , Methacrylates/administration & dosage , Phosphorylcholine/analogs & derivatives , ortho-Aminobenzoates/administration & dosage , Administration, Oral , Animals , Anti-Allergic Agents/chemistry , Anti-Allergic Agents/pharmacokinetics , Biological Availability , Crystallization , Male , Methacrylates/chemistry , Methacrylates/pharmacokinetics , Micelles , Particle Size , Phosphorylcholine/administration & dosage , Phosphorylcholine/chemistry , Phosphorylcholine/pharmacokinetics , Rats , Rats, Sprague-Dawley , Solubility , ortho-Aminobenzoates/chemistry , ortho-Aminobenzoates/pharmacokinetics
11.
Int J Pharm ; 448(1): 282-9, 2013 May 01.
Article in English | MEDLINE | ID: mdl-23528280

ABSTRACT

The main objective of this study was to improve the safety and oxidative stability of glycerol monooleate (GMO)-based dry-emulsion (DE) formulation containing cyclosporine A (CsA) for inhalation therapy. GMO or highly purified GMO (hpGMO) was used as surfactant for the DE formulations (GMO/DE or hpGMO/DE), the toxicological and physicochemical properties of which were characterized with a focus on oxidative stability, in vitro/in vivo toxicity, and dissolution property. Incubation of GMO at oxidation accelerating conditions for 10 days at 60°C resulted in the formation of lipid peroxides as evidenced by increased malondialdehyde (111 µmol/mg); however, hpGMO samples exhibited increase of only 20.7 µmol/mg in malondialdehyde level. No significant acute cytotoxicity was observed in rat alveolar L2 cells exposed to hpGMO (0.28mM), and intratracheal administration of hpGMO powder in rats did not cause an increase of the plasma LDH level. The hpGMO/DE exhibited marked improvement in dissolution behavior of CsA, and stable fine micelles with a mean diameter of 320 nm were formed when suspended in water. A respirable powder formulation of hpGMO/DE (hpGMO/DE-RP) was newly prepared, and its in vitro inhalation property and in vivo efficacy were also evaluated. The hpGMO/DE-RP exhibited high dispersibility in laser diffraction analysis and significantly improved potency to attenuate recruitment of inflammatory cells into airway and thickening of airway wall in an animal model. Thus, the strategic use of hpGMO would improve oxidative stability and local toxicity compared with a GMO-based DE formulation, and its application to RP formulation could be a promising approach for effective inhalation therapy.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Cyclosporine/administration & dosage , Glycerides/chemistry , Respiratory Therapy , Surface-Active Agents/chemistry , Animals , Antigens/administration & dosage , Asthma/drug therapy , Asthma/pathology , Cell Line , Disease Models, Animal , Emulsions , Male , Ovalbumin/administration & dosage , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/pathology , Rats , Rats, Sprague-Dawley
12.
Pharm Res ; 30(6): 1586-96, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23430486

ABSTRACT

PURPOSE: Orally-taken pirfenidone (PFD), an idiopathic pulmonary fibrosis drug, often causes severe phototoxicity. Present study aimed to develop a respirable powder formulation for PFD (PFD-RP) to minimize phototoxic risk. METHODS: Photochemical properties of PFD were examined using a reactive oxygen species (ROS) assay and photostability testing. PFD-RP was characterized with a focus on photostability, in vitro inhalation performance, and the efficacy in antigen-sensitized rats. Pharmacokinetic studies were conducted after oral and intratracheal administration of PFD formulations. RESULTS: Although PFD solution exhibited photodegradation under simulated sunlight (250 W/m²), both PFD powder and PFD-RP were photochemically stable. Laser diffraction and cascade impactor analyses on PFD-RP suggested its high dispersion and fine in vitro inhalation performance. Inhaled PFD-RP (300 µg-PFD/rat) could suppress antigen-evoked pulmonary inflammation in rats as evidenced by decreases in recruited inflammatory cells and neutrophilia-related biomarkers in the lung. Exposure of PFD to light-exposed tissues (skin and eye) after intratracheal administration of PFD-RP at a pharmacologically effective dose (300 µg-PFD/rat) was 90-130-fold less than that of the oral PFD dosage form at a phototoxic dose (160 mg/kg). CONCLUSIONS: PFD-RP might be an attractive alternative to the current oral PFD therapy with a better safety margin.


Subject(s)
Dermatitis, Phototoxic/prevention & control , Pulmonary Fibrosis/drug therapy , Pyridones/administration & dosage , Pyridones/chemistry , Administration, Inhalation , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/chemistry , Chemistry, Pharmaceutical/methods , Lung/drug effects , Male , Pharmaceutical Solutions/administration & dosage , Pharmaceutical Solutions/chemistry , Pneumonia/drug therapy , Powders/administration & dosage , Powders/chemistry , Rats , Rats, Sprague-Dawley
13.
Peptides ; 35(2): 182-9, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22484228

ABSTRACT

The present study was undertaken to develop a respirable sustained-release powder (RP) formulation of long-acting VIP derivative, [Arg(15, 20, 21), Leu(17)]-VIP-GRR (IK312532), using PLGA nanospheres (NS) with the aim of improving the duration of action. NS formulation of IK312532 (IK312532/NS) was prepared by an emulsion solvent diffusion method in oil, and a mixture of the IK312532/NS and erythritol was jet-milled and mixed with lactose carrier to obtain the IK312532/NS-RP. Physicochemical properties were characterized focusing on appearance, particle size, and drug release, and in vivo pharmacological effects were assessed in antigen-sensitized rats. The IK312532/NS with a diameter of 140 nm showed a biphasic release pattern in distilled water with ca. 20% initial burst for 30 min and a sustained slow release up to ca. 55% for 24h. Laser diffraction analysis demonstrated that IK312532/NS-RP had fine dispersibility and suitable particle size for inhalation. In antigen-sensitized rats, insufflated IK312532/NS-RP (10 µg of IK312532/rat) could suppress increases of granulocyte recruitment and myeloperoxidase in pulmonary tissue for up to 24h after antigen challenge, although IK312532-RP at the same dose was less effective with limited duration of action. From these findings, newly prepared IK312532/NS-RP might be of clinical importance in improving duration of action and medication compliance for treatment of airway inflammatory diseases.


Subject(s)
Asthma/drug therapy , Pneumonia/drug therapy , Vasoactive Intestinal Peptide/analogs & derivatives , Administration, Inhalation , Animals , Bronchoalveolar Lavage Fluid/cytology , Delayed-Action Preparations , Disease Models, Animal , Granulocytes/drug effects , Granulocytes/physiology , Lung/drug effects , Lung Diseases/drug therapy , Male , Nanospheres , Peroxidase/metabolism , Rats , Rats, Sprague-Dawley , Respiratory System/drug effects , Respiratory System/immunology , Vasoactive Intestinal Peptide/administration & dosage , Vasoactive Intestinal Peptide/pharmacology , Vasoactive Intestinal Peptide/therapeutic use
14.
J Pharm Sci ; 101(6): 2074-81, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22388976

ABSTRACT

The main purpose of the present study was to develop a respirable powder (RP) formulation of bleomycin (BLM) as a research tool for developing a pulmonary fibrosis animal model. The BLM-RP was prepared with a jet-milling system, the physicochemical properties of which were characterized focusing on morphology, stability, particle size distribution, and inhalation performance. Under an accelerated condition, the BLM-RP was superior to BLM solution in terms of its stability. Cascade impactor analyses demonstrated high inhalation performance with emitted dose and fine particle fraction of approximately 99% and 46%, respectively. Intratracheal administration of the BLM-RP (3 mg BLM/kg) in rats led to significant increases in collagen production and recruitment of inflammatory cells in lung by approximately 1.5- and 29-fold, respectively. The collagen overexpression was consistent with the results from picrosirius red staining of lung tissues in the rats treated with BLM-RP. Inhaled tranilast (TL; 100 µg/rat), an antifibrotic agent, could ameliorate inflammatory/fibrotic responses with reductions of recruited inflammatory cells and collagen content by 32% and 59%, respectively, validating the pulmonary fibrosis animal model. From these findings, the BLM-RP with improved stability could be a beneficial research tool for developing a pulmonary fibrosis model in drug discovery for antifibrotic drug candidates.


Subject(s)
Bleomycin/toxicity , Disease Models, Animal , Pulmonary Fibrosis/chemically induced , Animals , Bleomycin/chemistry , Male , Powders , Rats , Rats, Sprague-Dawley
15.
Drug Metab Pharmacokinet ; 27(4): 379-87, 2012.
Article in English | MEDLINE | ID: mdl-22240843

ABSTRACT

In the present study, amorphous solid dispersion (ASD) formulations of tranilast (TL) with 8 hydrophilic polymers were prepared by a solvent evaporation method with the aim of improving dissolution behavior in gastric fluid and thereby enhancing oral bioavailability. The physicochemical properties were characterized with a focus on morphology, crystallinity, thermal behavior, dissolution, drug-polymer interaction, and stability. Of all TL formulations, ASD formulation with Eudragit EPO exhibited the highest improvement in dissolution behavior with a 3,000-fold increase in the first-order dissolution rate under acidic conditions (pH 1.2). Spectroscopic studies using infrared and near-infrared analyses revealed the drug-polymer interaction in the Eudragit EPO-based ASD formulation. On the basis of dissolution, crystallinity, and stability data, the maximum allowable drug load in the Eudragit EPO-based ASD formulation was deduced to be ca. 50%. Pharmacokinetic profiling of orally dosed TL formulations in rats was also carried out using UPLC/ESI-MS. After oral administration of the Eudragit EPO-based ASD formulation in rats, enhanced TL exposure was observed with an increase of oral bioavailability by 19-fold, and the variation of AUC was ca. 4 times lower than that with crystalline TL. With these data, the ASD approach could be a viable formulation strategy for enhancing the wettability and oral bioavailability of TL, resulting in improved therapeutic potential of TL for the treatment of inflammatory diseases.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , ortho-Aminobenzoates/administration & dosage , ortho-Aminobenzoates/pharmacokinetics , Administration, Oral , Animals , Anti-Inflammatory Agents, Non-Steroidal/blood , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Area Under Curve , Biological Availability , Calorimetry, Differential Scanning , Chemistry, Pharmaceutical , Chromatography, Liquid , Crystallization , Crystallography, X-Ray , Drug Stability , Gastric Juice/chemistry , Hydrogen-Ion Concentration , Hydrophobic and Hydrophilic Interactions , Injections, Intravenous , Male , Metabolic Clearance Rate , Microscopy, Electron, Scanning , Microscopy, Polarization , Models, Biological , Polymethacrylic Acids/chemistry , Powder Diffraction , Rats , Rats, Sprague-Dawley , Solubility , Spectrometry, Mass, Electrospray Ionization , Spectroscopy, Fourier Transform Infrared , Spectroscopy, Near-Infrared , Technology, Pharmaceutical/methods , ortho-Aminobenzoates/blood , ortho-Aminobenzoates/chemistry
16.
Eur J Pharm Biopharm ; 80(1): 54-60, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22008148

ABSTRACT

The main purpose of the present study was to develop a novel respirable powder (RP) formulation of cyclosporine A (CsA) using a spray-dried O/W-emulsion (DE) system. DE formulation of CsA (DE/CsA) was prepared by spray-drying a mixture of erythritol and liquid O/W emulsion containing CsA, polyvinylpyrrolidone, and glyceryl monooleate as emulsifying agent. The DE/CsA powders were mixed with lactose carriers to obtain an RP formulation of DE/CsA (DE/CsA-RP), and its physicochemical, pharmacological, and pharmacokinetic properties were evaluated. Spray-dried DE/CsA exhibited significant improvement in dissolution behavior with ca. 4500-fold increase of dissolution rate, and then, nanoemulsified particles were reconstituted with a mean diameter of 317 nm. Laser diffraction analysis on the DE/CsA-RP suggested high dispersion of DE/CsA on the surface of the lactose carrier. Anti-inflammatory properties of the inhaled DE/CsA-RP were characterized in antigen-sensitized asthma/COPD-model rats, in which the DE/CsA-RP was more potent than the RP formulation of physical mixture containing CsA and erythritol in inhibiting inflammatory responses, possibly due to the improved dissolution behavior. Pharmacokinetic studies demonstrated that systemic exposure of CsA after intratracheal administration of the DE/CsA-RP at a pharmacologically effective dose (100 µg-CsA/rat) was 50-fold less than that of the oral CsA dosage form at a toxic dose (10 mg/kg). From these findings, use of inhalable DE formulation of CsA might be a promising approach for the treatment of airway inflammatory diseases with improved pharmacodynamics and lower systemic exposure.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/chemistry , Cyclosporine/administration & dosage , Cyclosporine/chemistry , Administration, Inhalation , Animals , Anti-Inflammatory Agents/pharmacokinetics , Asthma/drug therapy , Chemistry, Pharmaceutical/methods , Cyclosporine/pharmacokinetics , Drug Carriers/administration & dosage , Drug Carriers/chemistry , Emulsifying Agents/administration & dosage , Emulsifying Agents/chemistry , Emulsions/administration & dosage , Emulsions/chemistry , Emulsions/pharmacokinetics , Glycerides/administration & dosage , Glycerides/chemistry , Lactose/administration & dosage , Lactose/chemistry , Male , Particle Size , Povidone/administration & dosage , Povidone/chemistry , Powders/administration & dosage , Powders/chemistry , Powders/pharmacokinetics , Pulmonary Disease, Chronic Obstructive/drug therapy , Rats , Rats, Sprague-Dawley , Solubility
17.
Int J Pharm ; 410(1-2): 54-60, 2011 May 30.
Article in English | MEDLINE | ID: mdl-21419198

ABSTRACT

Vasoactive intestinal peptide (VIP) has been considered as a promising drug candidate for asthma and COPD because of its potent immunomodulating and anti-inflammatory activities. Recently, our group developed a new VIP derivative, [R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR (IK312548), with improved chemical and metabolic stability. In the present study, a dry powder inhaler system of IK312548 was designed for inhalation therapy with minimal systemic side effects, the physicochemical properties of which were also evaluated with a focus on morphology, particle size distribution, inhalation performance, and peptide stability. Laser diffraction and cascade impactor analysis suggested high dispersion and deposition in the respiratory organs with a fine particle fraction of 31.2%. According to UPLC/ESI-MS and circular dichroic spectral analyses, no significant changes in the purity and structure of VIP derivative were observed during preparation of respirable formulation. Anti-inflammatory properties of IK312548 respirable powder (RP) were characterized in antigen-sensitized asthma/COPD-model rats. There were marked inflammatory cells infiltrated into the lung tissues of experimental asthma/COPD-model rats; however, intratracheal administration of IK312548-RP led to significant reductions of recruited inflammatory cells in lung tissues and BALF by 72 and 78%, respectively. Thus, respirable powder formulation of IK312548 might be a promising medication for asthma, COPD, and other airway inflammatory diseases.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Asthma/drug therapy , Pulmonary Disease, Chronic Obstructive/drug therapy , Vasoactive Intestinal Peptide/analogs & derivatives , Administration, Inhalation , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacokinetics , Asthma/physiopathology , Disease Models, Animal , Drug Stability , Dry Powder Inhalers , Inflammation/drug therapy , Inflammation/physiopathology , Lung/drug effects , Lung/physiopathology , Male , Particle Size , Pulmonary Disease, Chronic Obstructive/physiopathology , Rats , Rats, Sprague-Dawley , Tissue Distribution , Vasoactive Intestinal Peptide/administration & dosage , Vasoactive Intestinal Peptide/pharmacokinetics , Vasoactive Intestinal Peptide/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...